Merck, PHR1296-1G, Bifonazole

General description
Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.
Bifonazole is a substituted imidazole analog with therapeutic potential in treating invasive mucosal infections. It exhibits antifungal activity by suppressing the proliferation of dermatophytes, yeasts and fungi affecting the skin and nails. Its mode of action involves blocking the fungal ergosterol biosynthetic pathway and additional inhibition of terpenoid biosynthesis.
Application
These Secondary Standards are qualified as Certified Reference Materials. These are suitable for use in several analytical applications including but not limited to pharma release testing, pharma method development for qualitative and quantitative analyses, food and beverage quality control testing, and other calibration requirements.
Bifonazole may be used as a pharmaceutical reference standard for the quantification of the analyte in pharmaceutical formulations using spectrophotometric technique.
Biochem/physiol Actions
Bifonazole is an imidazole-based anti-fungal agent with broad spectrum activity against many fungi, molds, yeast and some Gram-positive bacteria. Bifonazole inhibits ergosterol biosynthetic protein 28 and Cytochrome P450 2B4.
Analysis Note
These secondary standards offer multi-traceability to the US and EP primary standards, where they are available.
Other Notes
This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis.
To see an example of a Certificate of Analysis for this material enter LRAC3256 in the slot below. This is an example certificate only and may not be the lot that you receive.